


What is claimed is:

1. A compound of formula I:



wherein:

R¹ is hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of 2 to 6 carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

R² is hydrogen or alkyl of 1 to 6 carbons;

the group X—Y is -N=C(R³)-C(R⁴)=N-, -N=C(R³)-C(R⁵)=CH-, -N=C(R³)-N=CH-, -N=C(R³)-O-, -NH-C(R⁶)=N- or -NH-C(R⁷)=CH-;


R³ and R⁴ are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R⁵ is hydrogen or alkyl of 1 to 6 carbon atoms;

R⁶ is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R⁷ is hydrogen, halo, trifluoromethyl, pentafluoroethyl or alkyl of 1 to 6 carbon atoms;

Q is a heteroaryl moiety selected from the following:



wherein Z is NR^{12} , S, or O;

R^8 , R^9 , R^{10} , and R^{11} are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of 2 to 6 carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

R^{12} is hydrogen or alkyl of 1 to 6 carbon atoms;


m is 1 to 3;

n is 1 to 2; and

p is 0 to 3;


or pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein n is 2 and m is 1 or pharmaceutically acceptable salts thereof.
3. A compound according to claim 1, wherein p is 0 or pharmaceutically acceptable salts thereof.
4. A compound according to claim 1, wherein the group X-Y is $-\text{N}=\text{C}(\text{R}^3)-\text{C}(\text{R}^5)=\text{CH}-$ or $-\text{N}=\text{C}(\text{R}^3)-\text{O}-$ or pharmaceutically acceptable salts thereof.
5. A compound according to claim 1, wherein Q is a heteroaryl moiety of the formula



or pharmaceutically acceptable salts thereof.


6. A compound according to claim 1 having Formula Ia:



Ia

or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 having Formula Ib:



Ib

or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1, wherein said compound is N-[(cis)-3-(1H-indol-3-yl)cyclopentyl]-N-[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methylamine or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 1, wherein said compound is N-[(trans)-3-(1H-indol-3-yl)cyclopentyl]-N-[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methylamine or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methylamine or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 1, wherein said compound is N-[(1R,3S)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
12. A compound according to claim 1, wherein said compound is N-[(1S,3R)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 1, wherein said compound is N-[(trans)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1, wherein said compound is N-[(1R,3R)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
15. A compound according to claim 1, wherein said compound is N-[(1S,3S)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-methyl-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
17. A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-[[[(2S)-8-methyl-2,3-

dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 1, wherein said compound is N-[(1R,3S)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-(((2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.
19. A compound according to claim 1, wherein said compound is N-[(1S,3R)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-(((2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.
20. A compound according to claim 1, wherein said compound is N-[(trans)-3-(5-fluoro-1-methyl-1H-indol-3-yl)cyclopentyl]-N-(((2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.
21. A compound according to claim 1, wherein said compound is N-[(cis)-4-(5-fluoro-1H-indol-3-yl)cyclohexyl]-N-(((2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.
22. A compound according to claim 1, wherein said compound is N-[(trans)-4-(5-fluoro-1H-indol-3-yl)cyclohexyl]-N-(((2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl)methyl)amine or a pharmaceutically acceptable salt thereof.
23. A compound according to claim 1, wherein said compound is N-[(trans)-3-(5-Fluoro-1H-indol-3-yl)cyclopentyl]-N-(((8S)-2-methyl-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl)methyl)amine or a pharmaceutically acceptable salt thereof.

24. A compound according to claim 1, wherein said compound is N-[(cis)-3-(5-Fluoro-1H-indol-3-yl)cyclopentyl]-N-[[[(8S)-2-methyl-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl]methyl]amine or a pharmaceutically acceptable salt thereof.
25. A compound according to claim 1, wherein said compound is N-[(cis)-4-(5-fluoro-1H-indol-3-yl)cyclohexyl]-N-[[[(8S)-2-methyl-7,8-dihydro[1,4]dioxino[2,3-g][1,3]benzoxazol-8-yl]methyl]amine; or a pharmaceutically acceptable salt thereof.
26. A compound according to claim 1, wherein said compound is N-[(1R*,3S*)-3-(5-fluoro-1H-indol-3-yl)cyclopentyl]-N-methyl-N-[[[(2S)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl]amine; or a pharmaceutically acceptable salt thereof.
27. A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction,
comprising the step of providing to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1.
28. A method according to claim 27, wherein the condition is depression.
29. A method according to claim 27, wherein the condition is selected from the group consisting of obsessive compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
30. A pharmaceutical composition, comprising:

an effective amount of compound according to claim 1 or
pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier or excipient.